TWP
CRSP icon

Tyche Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

Tyche Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$488K Hold
8,950
– – 0.07% 193
2026
Q1 		$426K Hold
8,950
– – 0.07% 220
2025
Q4 		$469K Sell
8,950
-850
-9% -$50.9K 0.07% 197
2025
Q3 		$635K Sell
9,800
-5,985
-38% -$344K 0.11% 147
2025
Q2 		$768K Buy
15,785
+6,600
+72% +$255K 0.15% 103
2025
Q1 		$313K Buy
9,185
+850
+10% +$36K 0.07% 190
2024
Q4 		$328K Buy
+8,335
New +$394K 0.07% 203

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tyche Wealth Partners's CRSP Position: Q2 2026 in Review

Tyche Wealth Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 8,950 shares worth $488K. The position accounts for 0.07% of the portfolio, ranked #193.

Tyche Wealth Partners first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. The position peaked at $768K in Q2 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Tyche Wealth Partners held 8,950 shares of CRISPR Therapeutics worth $488K as of Q2 2026.
  • Tyche Wealth Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.07% of Tyche Wealth Partners's portfolio in Q2 2026, its #193 holding.
  • Tyche Wealth Partners first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Tyche Wealth Partners's CRISPR Therapeutics position peaked at $768K in Q2 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Tyche Wealth Partners's 13F filing for Q2 2026, filed 6 Aug 2026.